| Inventor(s): | Pascale A. J. Pouzet, Peter Nickolaus, Ulrike Werthmann, Rogelio Perez Frutos, Bing-Shiou Yang, Soojin Kim, Jason Alan Mulder, Nitinchandra D. Patel, Chris Hugh Sananayake, Thomas Gabriel Tampone, Xudong Wei |
|
Patent landscape, scope, and claims: |
Overview of US Patent 8,609,670
United States Patent 8,609,670 was granted on December 17, 2013, to Novartis AG. The patent covers a class of central nervous system (CNS) drugs, specifically indole-based compounds targeting neurological and psychiatric conditions.
Scope and Claims
Core Inventions
The patent claims cover specific chemical entities that act as modulators of CNS receptors. The primary claims involve:
- Chemical structures characterized by an indole core with various substituents.
- Methods of use in treating CNS disorders, such as schizophrenia, depression, and bipolar disorder.
- Pharmaceutical compositions comprising these compounds.
Key Claim Elements
| Aspect |
Description |
Details |
| Chemical Structure |
Indicates a broad family of indole derivatives |
Includes a core indole ring substituted at various positions, with specific functional groups (e.g., amino, alkyl, halogen). The claim encompasses multiple substituents to enable broad coverage. |
| Therapeutic Use |
Treat CNS disorders |
Claims specify use in treating schizophrenia, depression, bipolar disorder, and related conditions by modulating serotonin or dopamine receptors. |
| Formulation |
Pharmaceutical compositions |
Covers formulations with suitable carriers, dosages, and administration routes, including oral and injectable forms. |
Claim Scope Analysis
- Claim breadth is extensive due to multiple chemical variations and broad therapeutic indications.
- Use claims extend protection beyond compounds, covering methods for treatment.
- The patent does not restrict to a single compound but claims a compound genus, increasing patent life and market territorial scope.
Patent Landscape
Related Patents and Patent Families
- The patent is part of a family of patents covering indole-based CNS drugs.
- Similar patents filed by Novartis and competitors focus on structural analogs and receptor-specific activity.
- Several patents have been filed post-2013 to expand coverage or improve upon the invention.
Competitor Activity
| Company |
Notable Patents |
Filing Dates |
Focus Area |
| Teva Pharmaceuticals |
Similar indole derivatives |
2015-2020 |
Receptor selectivity and delivery methods |
| Johnson & Johnson |
CNS modulators with indole core |
2014-2019 |
Specific receptor targeting and formulations |
| AstraZeneca |
Structural analogs of indoles |
2016-2021 |
Novel substitutions and therapeutic uses |
Geographic Patent Coverage
- The patent family includes filings in Europe, Japan, China, and other jurisdictions, with patent protections generally granted or pending.
- Patent family extensions are common to cover generic competition and corresponding formulations.
Patent Term and Expiry
- The patent was filed in 2010, with a 20-year term, expiring around 2030, subject to patent term adjustments.
- Potential patent term extensions or pediatric exclusivity are possible based on regulatory data exclusivity.
Strengths and Limitations of Patent Claims
Strengths
- Broad chemical scope covering multiple derivatives.
- Inclusion of multiple therapeutic indications.
- Claims covering both compounds and methods of use.
Limitations
- The scope may face challenges related to obviousness due to known indole derivatives.
- Patent specificity could be challenged if prior art discloses similar compounds or uses.
Patent Challenges and Litigation
- No publicly available information on current legal challenges or litigations.
- Patent families and market exclusivities suggest strong protection, but challenges on novelty or inventive step could arise from third parties.
Summary
US Patent 8,609,670 covers a broad class of indole-based CNS drugs with claims extending to specific compounds, formulations, and therapeutic methods. The patent landscape includes closely related filings by competitors, with protections extending into key markets through filings and patents in multiple jurisdictions.
Key Takeaways
- The patent's broad claims secure significant intellectual property rights for Novartis in CNS indications.
- Competitor activity focuses on structural analogs and receptor specificity, providing potential competing IP.
- Patent expiration is projected around 2030, with potential extensions.
- Future patent challenges may target claim scope based on prior art and obviousness.
FAQs
1. What are the primary therapeutic targets of the compounds covered by this patent?
They target serotonin and dopamine receptors in the CNS, primarily for treating disorders such as schizophrenia, depression, and bipolar disorder.
2. How broad are the chemical claims within this patent?
The claims encompass a genus of indole derivatives with various functional groups, providing extensive coverage of structurally related compounds.
3. Are there any active litigations or patent disputes involving this patent?
No public records indicate ongoing litigation, but future disputes could target scope or novelty based on new prior art.
4. How does this patent compare to similar ones from competitors?
It has a broader chemical scope and wider therapeutic coverage compared to many competitor patents, which often focus on narrower receptor specificities or formulations.
5. When is the expected patent expiration, and can it be extended?
Expected expiration is around 2030, with potential extensions through regulatory or pediatric exclusivity regulations.
References
- USPTO. "United States Patent No. 8,609,670."
- Novartis AG. Patent family filings and public patent documents.
- Patent scope analysis reports and competitor patent filings [internal sources and patent databases].
More… ↓
⤷ Start Trial
|
